Pharmacally
Tedopi
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Tedopi
Clinical TrialsOSE’s Tedopi Shows Encouraging Survival Results in NSCLC TrialOSE Immunotherapeutics reported one-year overall survival rates of 47% and 46% with Tedopi plus docetaxel and Tedopi plus nivolumab, respectively, in the Combi-TED Phase 2 trial.Fact-Checked
Health TidingsOSE Reports Positive Tedopi Results in Metastatic NSCLCOSE Immunotherapeutics reported one-year overall survival rates of 47% with Tedopi plus docetaxel and 46% with Tedopi plus nivolumab in the Combi-TED Phase 2 trial.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.